Literature DB >> 28889723

Expression of C-myc and β-catenin and their correlation in triple negative breast cancer.

Jiankui Wang1, Mei Li2, Dedian Chen1, Jianyun Nie1, Yan Xi3, Xiaojuan Yang1, Yun Chen2, Zhuanqing Yang4.   

Abstract

BACKGROUND: The present study was planned to study the expression of C-myc and β-catenin in triple negative breast cancer (TNBC) tissue. Furthermore, their relations to clinical features of the tumor and the survival prognosis were also studied. Additionally, correlation was evaluated between the expression of C-myc and β-catenin to provide the theoretical basis for the targeted therapy of TNBC.
METHODS: Sixty cases of patients diagnosed with TNBC for the first time were selected for the study. The immumo-histochemical staining was employed to detect the positive expression rates of C-myc and β-catenin in cancer tissues and normal mammary tissues 3 cm away from the carcinoma. Fluorescence in situ hybridization (FISH) was used to test the gene amplification of C-myc in order to analyze the relation between C-myc and the protein expression of β-catenin. Further, kept the median follow-up time to 25.0 months in order to compare the survival prognosis.
RESULTS: The positive expression rates of C-myc and β-catenin in cancer tissues were significantly higher than those in precancerous normal tissues (P<0.05). Furthermore, the expression rates were related with the diameter of tumor, clinical staging, pathological grading and lymphatic metastasis (P<0.5). There were 33 cases that exhibited an increase in C-myc gene copy number and the gene amplification was observed to be 55% in total. On the other hand, patients with positive expression of C-myc and β-catenin protein exhibited a shortened disease-free survival without tumor with an increasing recurrence rate and lower survival rate (P<0.05).
CONCLUSIONS: The present study concludes that the positive expression of C-myc and β-catenin in TNBC tissue might be closely correlated with clinical features of cancer and the survival prognosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28889723     DOI: 10.23736/S0026-4806.17.05213-2

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  7 in total

1.  Cryptanshinone Inhibits the Glycolysis and Inhibits Cell Migration Through PKM2/β-Catenin Axis in Breast Cancer.

Authors:  Jiefeng Zhou; Chih-Ming Su; Hsin-An Chen; Shicong Du; Chang-Wei Li; Haoran Wu; Shin-Han Tsai; Yu-Ting Yeh
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

2.  TMED3 Promotes Proliferation and Migration in Breast Cancer Cells by Activating Wnt/β-Catenin Signaling.

Authors:  Xiumei Zhang; Yalan Luo; Qingchang Li
Journal:  Onco Targets Ther       Date:  2020-06-19       Impact factor: 4.147

3.  MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1.

Authors:  Xiao-Hui Gao; Ya-Li Zhang; Zhi-Ye Zhang; Shuang-Shuang Guo; Xiao-Bing Chen; Yan-Zhen Guo
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

4.  The Shuganhuazheng Formula in Triple-Negative Breast Cancer: A Study Based on Network Pharmacology and In Vivo Experiments.

Authors:  Bo Wang; Rui Fei; Yan Yang; Niancai Jing; Yi Lu; Hongyu Xiao; Jili Yang; Yue Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-14       Impact factor: 2.629

Review 5.  Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review.

Authors:  Davood Dalil; Saeid Iranzadeh; Soroush Kohansal
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

6.  The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs.

Authors:  Eman Sami; Danielle Bogan; Alfredo Molinolo; Jim Koziol; Wael M ElShamy
Journal:  Cancer Gene Ther       Date:  2021-03-15       Impact factor: 5.987

7.  Honokiol inhibits the growth of SKBR3 cells.

Authors:  He Shi; Yange Wang; Mengli Yao; Dian Zhang; Wenli Fang; Ting Zhou; Delu Gan; Shujun Yue; Husun Qian; Tingmei Chen
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.